Alabama is currently home to 1236 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Birmingham, Mobile, Huntsville and Anniston. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Dose Escalation Trial of Safety, Pharmacokinetic/Pharmacodynamic and Preliminary Clinical Activity of Briquilimab in Adult Patients with Chronic Spontaneous Urticaria (CSU)
NCT06162728
Recruiting
This trial will be performed as a three-part dose escalating clinical trial where Parts 1 is open label and Parts 2 and 3 are randomized, double-blinded, and placebo-controlled. The trial is intended to determine the safety and tolerability and assess the preliminary efficacy of briquilimab in adult participants with chronic spontaneous urticaria (CSU), who remain symptomatic despite treatment with H1 antihistamines and omalizumab. Additionally, pharmacokinetic (PK) properties of briquilimab, a... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/31/2025
Locations: Site 118, Birmingham, Alabama
Conditions: Chronic Spontaneous Urticaria
Register for Updates
The Presence of a Therapy Dog Reduces Pain and Anxiety During Pediatric Elbow Pin Removal
NCT05830201
Recruiting
The purpose of this research study is to assess whether the presence of therapy dogs can reduce pain and anxiety in children ages 3 to 10 having pins removed from their elbow.
Gender:
ALL
Ages:
Between 3 years and 10 years
Trial Updated:
01/31/2025
Locations: UAB, Birmingham, Alabama
Conditions: Elbow Injury
Register for Updates
Efficacy and Safety of Iptacopan (LNP023) in Adult Patients With Atypical Hemolytic Uremic Syndrome Naive to Complement Inhibitor Therapy
NCT04889430
Recruiting
The purpose of this Phase 3 study is to determine whether iptacopan (LNP023) is efficacious and safe for the treatment of aHUS in adult patients who are treatment naive to complement inhibitor therapy.
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
01/31/2025
Locations: Uni Of Alabama At Birmingham, Birmingham, Alabama
Conditions: Atypical Hemolytic Uremic Syndrome
Register for Updates
Video Telehealth Exercise Training in Cystic Fibrosis
NCT04680403
Recruiting
The purpose of this research study is to begin an exercise program for patients with a cystic fibrosis (CF) exacerbation.
Gender:
ALL
Ages:
19 years and above
Trial Updated:
01/31/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Cystic Fibrosis
Register for Updates
RESTORE: REducing Future FractureS and Improving OuTcOmes of FRagility FracturE
NCT06455085
Recruiting
RESTORE tests whether Augmented-FLS, where patients are contacted by a patient navigator (serving as the liaison) and referred to a bone health provider, is better than Enhanced Usual Care, which includes patient and PCP education and activation. We also aim to determine the influence of age, race, ethnicity, sex, poverty level, geographic region, and timing of entry into the trial after a fracture on the effectiveness of the two strategies.
Gender:
ALL
Ages:
50 years and above
Trial Updated:
01/30/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Osteoporosis, Osteoporotic Fractures
Register for Updates
A Stakeholder-enhanced Intervention to Improve the Decisional Partnership of Chronic Kidney Disease Dyads (IMPART)
NCT06173323
Recruiting
Using a highly innovative methodology, the Multiphase Optimization Strategy (MOST), the purpose of this study is to pilot test, an optimization trial approach to develop and refine the decision partnering skills of persons with stage 4 chronic kidney disease and their caregivers. Using a 2x2x2 full factorial design, 64 dyads (patients and one identified caregiver) will be randomized to receive one or more lay coach-delivered decision partnering training components, based on Pearlin's Stress-Heal... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/29/2025
Locations: Shena Gazaway, Birmingham, Alabama
Conditions: Decision Making, Shared, Family Caregiving, Chronic Kidney Disease
Register for Updates
Clinical Trial to Evaluate the Safety and Effectiveness of Using the Tendyne Transcatheter Mitral Valve System for the Treatment of Symptomatic Mitral Regurgitation
NCT03433274
Recruiting
Prospective, controlled, multicenter clinical investigation with four trial cohorts: Randomized, Non-repairable, Severe Mitral Annular Calcification (MAC) and Severe Mitral Annular Calcification Continued Access Protocol (MAC CAP). Subjects in the Randomized cohort will be randomized in a 1:1 ratio to the trial device or to the MitraClip system. Subjects in the Non-repairable, Severe MAC, and Severe MAC CAP cohorts will receive the trial device. The objective of the Clinical Trial to Evaluate t... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/29/2025
Locations: Princeton Baptist Medical Center, Birmingham, Alabama
Conditions: Mitral Regurgitation, Mitral Insufficiency, Mitral Valve Insufficiency, Cardiovascular Diseases, Valve Disease, Heart, Heart Valve Diseases, Functional Mitral Regurgitation, Degenerative Mitral Valve Disease
Register for Updates
Voice and Swallowing Outcomes Following Revision Anterior Cervical Spine Surgery
NCT01017055
Recruiting
Evaluate voice and swallowing outcomes post operatively.
Gender:
ALL
Ages:
19 years and above
Trial Updated:
01/29/2025
Locations: UAB, Birmingham, Alabama
Conditions: Dysphagia, Dysphonia
Register for Updates
Prospective Research Assessment in Multiple Myeloma: An Observational Evaluation (PREAMBLE)
NCT01838512
Recruiting
The purpose of this study is to assess the clinical effectiveness of all approved multiple myeloma (MM) therapies in the newly-diagnosed (NDMM) and the relapsed/refractory MM (RRMM) settings in real-world clinical practice.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/28/2025
Locations: Local Institution, Birmingham, Alabama
Conditions: Multiple Myeloma
Register for Updates
Study of Pembrolizumab and M032 (NSC 733972)
NCT05084430
Recruiting
This Phase I (Cohort I and Cohort II) and Phase II trial is designed to confirm the safety and tolerability of Pembrolizumab when given in conjunction with M032, an Oncolytic Herpes Simplex Virus (oHSV) that expresses IL-12 and perform the Phase II portion using a Recommended Phase 2 Dose (RP2D) of M032 (provided by the Phase I) when given in conjunction with Pembrolizumab for recurrent malignant glioma (glioblastoma multiforme, anaplastic astrocytoma, or glio-sarcoma).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/27/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Glioblastoma Multiforme, Anaplastic Astrocytoma, Gliosarcoma
Register for Updates
Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity (ICANS) Related to CAR-T Cell Therapy
NCT04975555
Recruiting
This study will evaluate the use of siltuximab to decrease the severity of cytokine release syndrome (CRS) and immune effector cell-associated neurological syndrome (ICANS) in patients who will receive chimeric antigen receptor (CAR) T-cell therapy for the treatment of hematological malignancies.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/24/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Cytokine Release Syndrome, ICANS, Lymphoma, Non-Hodgkin, Multiple Myeloma, Acute Lymphoblastic Leukemia
Register for Updates
A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus
NCT04961567
Recruiting
In this study, researchers will learn more about a study drug called litifilimab (BIIB059) in participants with systemic lupus erythematosus (SLE). The study will focus on participants who have active disease and are already taking standard of care medications. These may include antimalarials, steroids, and immunosuppressants. The main objective of the study is to learn about the effect litifilimab has on lowering the activity of the disease. The main question researchers want to answer is: -... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/23/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Lupus Erythematosus, Systemic
Register for Updates